Australia Sees Sharp Decline in Pregabalin Misuse Following New Safety Measures

Regulatory Interventions and Public Awareness

A study published in The BMJ indicates that Australia has successfully curbed the rising misuse of pregabalin, a medication commonly used for nerve pain, epilepsy, and anxiety. Between 2018 and 2024, researchers observed a significant departure from previous trends, with prescriptions falling 25% below expected levels and calls to poison centers regarding intentional poisoning dropping by 47%.

The decline followed a series of public health interventions, including high-profile media reporting on the drug's risks, stricter prescribing limits, and the introduction of boxed warnings. These measures were implemented as global health authorities raised alarms about increasing rates of dependence and overdose deaths associated with gabapentinoids, the class of drugs to which pregabalin belongs. In some regions, such as the United Kingdom, deaths involving these substances doubled in recent years, prompting international concern.

While the results are promising, the researchers emphasized that the study was observational and cannot confirm a direct cause-and-effect relationship. The data only tracked subsidized prescriptions and could not determine if patients were switching to other substances, such as opioids, to manage their symptoms. Furthermore, despite the decline, overall usage remains higher than what would be expected if the drug were only used for its officially approved medical indications.

Medical experts suggest that pregabalin should be reserved for specific conditions like diabetic nerve pain or fibromyalgia, rather than being used as a general analgesic for back pain or sciatica. What to know: Patients should discuss the specific benefits and risks of pregabalin with their doctor and avoid escalating doses without medical supervision.